Abstract
Hemoglobin A1c (HbA1c)2 measurement has been a standard of care for patients with either type 1 or type 2 diabetes for nearly 4 decades. Studies such as the Diabetes Control and Complications trial in type 1 diabetes and the United Kingdom Prospective Diabetes Study in type 2 diabetes in the 1990s have shown how hyperglycemia, as assessed by HbA1c, is associated with the long-term risk of the micro- and macrovascular complications of the disease and the likelihood of having a severe hypoglycemic episode (1, 2). The analytical performance specification (APS) required of a particular test—defining how accurate and/or precise the measurement should be for clinical purposes—is preferably based on data from outcome studies. However, it is uncommon for this information to exist for many routinely requested tests; therefore, less ideal alternatives, such as using biological variation or state-of-the-art technique for the measurement, are often used to derive the APS instead (3). With studies such as the Diabetes Control and Complications trial and United Kingdom Prospective Diabetes trial, HbA1c is one of the few examples in which trial data can directly inform the APS. The IFCC has developed 2 models of quality (i.e., APS) targets for HbA1c, one based on biological variation and the other on clinical outcomes (4). For the latter, a total allowable …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.